NCT05988814View on ClinicalTrials.gov

Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 24, 2024

Primary Completion Date

July 24, 2029

Study Completion Date

July 24, 2029

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

FOLFIRINOX treatment

"Treatment with FOLFIRINOX3 will be administered with a maximum of 16 courses divided into two 8-course doses.~Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression"

Trial Locations (1)

21000

RECRUITING

Centre Georges-François Leclerc, Dijon

All Listed Sponsors
lead

Centre Georges Francois Leclerc

OTHER